Ocular Pharmacokinetics of AzaSite Xtra—2% Azithromycin Formulated in a DuraSite Delivery System

REFERENCES

• Hoepelman I M, Schneider M ME. Azithromycin: The first of tissue-selective azalides. Int J Antimicrob Agents 1995; 5: 145–167
   PubMed Web of Science ®Google Scholar
• West S K. Azithromycin for control of trachoma. Commun Eye Health 1999; 12(32)55–56
   PubMedGoogle Scholar
• Ianaro A, Ialenti A, Maffia P, Sautebin L, Rombola L, Carnuccio R, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000; 292: 156–163
   PubMed Web of Science ®Google Scholar
• Scaglione F, Rossoni G. Comparative anti-inflammatory effects of roxithromycin, azithromycin, and clarithromycin. J Antimicrob Chemother 1998; 41(suppl B)47–50
   PubMedGoogle Scholar
• Tkalcevic V I, Bosnjak B, Hrvacic B, Bosnar M, Marjanovic N, Ferencic Z, et al. Anti-inflammatory activity of azithromycin attenuates the effects of lipopolysaccharide administration in mice. Eur J Pharmacol 2006; 539: 131–138
   PubMed Web of Science ®Google Scholar
• Bowman L M, Si E, Pang J, Friedlaender M. Development of a commercial eye drop formulation of azithromycin. E-abstract 772. Presented at The Association for Research in Vision and Ophthalmology Annual Meeting, Fort Lauderdale, FL, May, 5–102007
   Google Scholar
• Protzko E, Bowman L, Shapiro A, et al. Phase 3 safety comparisons for 1.0% azithromycin in a polymeric mucoadhesive eye drop vs. 0.3% tobramycin eye drops for bacterial conjunctivitis in AzaSite Study Group. Invest Ophthalmol Vis Sci 2007; 48: 3427–3431
   Web of Science ®Google Scholar
• Abelson M B, Heller W H, Shapiro A, et al. Clinical cure of bacterial conjunctivitis with azithromycin 1% eye drops: Double-masked randomized clinical trial of safety and efficacy. Am J Ophthalmol 2008; 145: 959–965
   PubMed Web of Science ®Google Scholar
• Cochereau I, Meddeb-Ouertani A, Khairallah M, et al. 3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: Multicentre, randomized, and controlled trial in adults and children. Br J Ophthalmol 2007; 91: 465–469
   PubMed Web of Science ®Google Scholar
• Denis F, Chaumeil C, Goldschmidt P, Delval L, Pouliquen P, et al. Microbiological efficacy of 3-day treatment with azithromycin 1.5% eye-drops for purulent bacterial conjunctivitis. Eur J Ophthalmol 2008; 18(6)858–868
   PubMed Web of Science ®Google Scholar
• Association for Research in Vision and Ophthalmology. Handbook for the Use of Animals in Biomedical Research, 2nd ed. Association for Research in Vision and Ophthalmology, Rockville, MD 1993
   Google Scholar
• Gigliotti F, Williams W T, Hayden F G, Hendley J O. Etiology of acute conjunctivitis in children. J Pediatr 1981; 98(4)531–536
   PubMed Web of Science ®Google Scholar
• Seal D V, Barrett S P, McGill J I. Aetiology and treatment of acute bacterial infection of the external eye. Br J Ophthalmol 1982; 66: 357–360
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Pneumococcal conjunctivitis at an elementary cchool—Maine, September 20–December 6, 2002. MMWR Morb Mortal Wkly Rep 2003; 52: 64–66
   PubMedGoogle Scholar
• American Academy of Ophthalmology. Conjunctivitis, Preferred Practice Pattern. American Academy of Ophthalmology, San Francisco, CA 2003, Available at www.aao.org/ppp
   Google Scholar
• Hwang D G, Schanzlin, Rotberg M H, Foulks G, Raizman M B. Levofloxacin Bacterial Conjunctivitis Place-Controlled Study Group. A phase III, placebo controlled clinical trial of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Br J Ophthalmol 2003; 87: 1004–1009
   PubMed Web of Science ®Google Scholar
• Fluoroquinolone antimicrobial drugs, Accessed at http://www.fda.gov/medwatch/on071808 MedWatch 070808
   Google Scholar
• Asbell P A, Colby K A, Deng S, McDonnell P, Meisler D M, et al. Ocular TRUST: Nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol 2008; 145(6)951–958
   PubMed Web of Science ®Google Scholar
• Craig W A. Does the dose matter?. Clin Infect Dis 2001; 33(Suppl 3)S233–237
   PubMed Web of Science ®Google Scholar
• Jacobs M R. How can we predict bacterial eradication?. Int J Infect Dis 2003; 7: S13–S20
   PubMedGoogle Scholar
• Amar T, Gaillaud T, Elena P P. Ocular pharmacokinetic study following single and multiple azithromycin administrations in pigmented rabbits. Curr Eye Res 2008; 33: 149–158
   PubMed Web of Science ®Google Scholar
• Arquedas A, Loaiza C, Soley C. Single dose azithromycin for the treatment of uncomplicated otitis media. Pediatr Infect Dis J 2004; 23: S108–S114
   PubMed Web of Science ®Google Scholar
• Jenkins S G, Brown S D, Farrell D J. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: Update from PROTEKT U.S. years 1–4. Ann Clin Microbiol Antimicrob 2008; 7: 1–11
   PubMedGoogle Scholar
• Blumer J L. Evolution of a new drug formulation: The rationale for high-dose, short-course therapy with azithromycin. Int J Antimicrob Agents 2005; 26(Suppl 3)S143–S147
   PubMedGoogle Scholar
• Granet D B, Lichtenstein S J, Onofrey B, et al. An assessment of the tolerability of moxifloxacin 0.5% compared to azithromycin 1.0% in DuraSite. Clin Ophthalmol 2007; 1(4)519–525
   PubMedGoogle Scholar
• Si E C, Bowman L M, Roy S D. Ocular bioavailability and systemic levels of an ophthalmic formulation of azithromycin, ISV-401. Presented at The Association for Research in Vision and Ophthalmology Annual Meeting, Fort Lauderdale, FL, May, 4–82003, E-Abstract 1461
   Google Scholar
• Amsden G W, Nafziger A N, Foulds G. Pharmacokinetics in serum and leukocyte exposures of azithromycin, 1500 milligrams, given over a 3- or 5-day period in health subjects. Antimicrob Agents Chemother 1999; 43(1)163–165
   PubMed Web of Science ®Google Scholar
• Dunn C J, Barradell L B. Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. Drugs 1996; 51(3)483–505
   PubMed Web of Science ®Google Scholar